HomeCompareQNNTF vs EPRT

QNNTF vs EPRT: Dividend Comparison 2026

QNNTF yields 2000.00% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QNNTF wins by $9939315158.47M in total portfolio value
10 years
QNNTF
QNNTF
● Live price
2000.00%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9939315158.53M
Annual income
$9,049,252,674,478,578.00
Full QNNTF calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — QNNTF vs EPRT

📍 QNNTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQNNTFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QNNTF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
QNNTF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QNNTF
Annual income on $10K today (after 15% tax)
$170,000.00/yr
After 10yr DRIP, annual income (after tax)
$7,691,864,773,306,791.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, QNNTF beats the other by $7,691,864,773,295,596.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QNNTF + EPRT for your $10,000?

QNNTF: 50%EPRT: 50%
100% EPRT50/50100% QNNTF
Portfolio after 10yr
$4969657579.30M
Annual income
$4,524,626,337,245,874.00/yr
Blended yield
91.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

QNNTF
No analyst data
Altman Z
-79.6
Piotroski
4/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QNNTF buys
0
EPRT buys
0
No recent congressional trades found for QNNTF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQNNTFEPRT
Forward yield2000.00%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$9939315158.53M$64.3K
Annual income after 10y$9,049,252,674,478,578.00$13,170.85
Total dividends collected$9876141646.27M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: QNNTF vs EPRT ($10,000, DRIP)

YearQNNTF PortfolioQNNTF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$210,700$200,000.00$11,212$512.01+$199.5KQNNTF
2$4,163,767$3,938,317.76$12,689$692.09+$4.15MQNNTF
3$77,191,133$72,735,902.82$14,521$944.30+$77.18MQNNTF
4$1,342,813,676$1,260,219,163.76$16,841$1,302.88+$1342.80MQNNTF
5$21,925,333,121$20,488,522,486.99$19,841$1,821.64+$21925.31MQNNTF
6$336,109,296,351$312,649,189,912.21$23,818$2,587.47+$336109.27MQNNTF
7$4,838,913,266,619$4,479,276,319,522.88$29,230$3,744.65+$4838913.24MQNNTF
8$65,446,276,951,058$60,268,639,755,775.59$36,816$5,540.38+$65446276.91MQNNTF
9$831,834,097,245,644$761,806,580,908,011.90$47,806$8,413.17+$831834097.20MQNNTF
10$9,939,315,158,531,418$9,049,252,674,478,578.00$64,324$13,170.85+$9939315158.47MQNNTF

QNNTF vs EPRT: Complete Analysis 2026

QNNTFStock

Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.

Full QNNTF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this QNNTF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QNNTF vs SCHDQNNTF vs JEPIQNNTF vs OQNNTF vs KOQNNTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.